Management of Acute Coronary Syndrome - Non-ST-Elevation Myocardial Infarction (ACS-NSTEMI)

Introduction to Management Strategies

The European Society of Cardiology recommends that the management of NSTEMI is fundamentally driven by the need to prevent recurrent myocardial ischemia, reduce infarct size, and prevent death through immediate antithrombotic therapy combined with risk-stratified coronary revascularization 1, 2, 3

NSTEMI results from coronary atherosclerotic plaque rupture or erosion with subsequent thrombus formation causing incomplete coronary occlusion, leading to cardiomyocyte necrosis measured by troponin elevation 3

The American College of Cardiology recommends aspirin (150-300 mg loading dose, then 75-100 mg daily) plus a P2Y12 inhibitor must be initiated immediately to halt platelet-mediated thrombus propagation, which is the primary driver of recurrent ischemic events and infarct extension 1, 2, 4, 5
Ticagrelor (180 mg loading, 90 mg twice daily) is preferred over clopidogrel for all moderate-to-high risk patients regardless of management strategy, as it provides more potent and consistent platelet inhibition 1, 6, 4
Prasugrel (60 mg loading, 10 mg daily; reduce to 5 mg if age ≥75 or weight <60 kg) is recommended only after coronary angiography and prior to PCI 2, 7, 4

Immediate anticoagulation prevents thrombin-mediated thrombus propagation and must be initiated alongside antiplatelet therapy, with fondaparinux (2.5 mg subcutaneously once daily) having the best efficacy-safety profile for conservative management 2, 7, 8, 4

The European Society of Cardiology recommends that the timing of coronary angiography is determined by risk stratification, as higher-risk patients derive greater mortality benefit from earlier revascularization while lower-risk patients can be managed selectively 1, 2, 6, 3, 9, 10
Very high-risk patients should proceed immediately to catheterization laboratory if any of the following are present: hemodynamic instability or cardiogenic shock, recurrent or ongoing chest pain refractory to medical treatment, life-threatening arrhythmias or cardiac arrest, mechanical complications of MI, acute heart failure with refractory angina or ST deviation, or recurrent dynamic ST- or T-wave changes 1, 6, 9
High-risk patients should perform coronary angiography within 24 hours if any of the following are present: rise or fall in cardiac troponin compatible with MI, dynamic ST- or T-wave changes, GRACE score >140 1, 6, 9, 10

High-sensitivity troponin measured at 0 and 1 hour (or 0 and 2 hours if 1-hour algorithm unavailable) allows rapid rule-in and rule-out of MI with sensitivity and NPV ≥99% 1, 6, 3

Administer sublingual or IV nitroglycerin for ongoing chest pain unless systolic BP <90 mmHg, >30 mmHg below baseline, severe bradycardia <50 bpm, or tachycardia >100 bpm without heart failure 2, 7, 8, 11
Initiate beta-blockers early in patients without contraindications (heart failure, hypotension, bradycardia, or heart block) 4

Initiate high-intensity statin immediately regardless of baseline cholesterol, as statins reduce recurrent ischemic events through plaque stabilization and anti-inflammatory effects beyond LDL lowering 4, 5
ACE inhibitors or ARBs are indicated for LVEF ≤40%, heart failure, hypertension, or diabetes, as RAAS blockade reduces adverse remodeling and improves survival in patients with LV dysfunction 3, 5
Continue aspirin plus P2Y12 inhibitor for 12 months unless excessive bleeding risk, then transition to aspirin monotherapy indefinitely, as 12 months of DAPT balances ischemic event reduction against bleeding risk 1, 6, 4, 5

Radial access is preferred over femoral access to reduce bleeding complications 2, 7, 8
Drug-eluting stents are recommended over bare-metal stents for any PCI, as drug-eluting stents reduce restenosis rates 5

Adjust anticoagulant and antiplatelet doses according to renal function; use low- or iso-osmolar contrast if angiography performed in patients with renal impairment 4
Apply same diagnostic and therapeutic strategies but reduce prasugrel to 5 mg daily if used; adjust antithrombotic dosing based on renal function and bleeding risk in elderly patients (≥75 years) 4
Transition from triple therapy (aspirin + clopidogrel + OAC) to dual therapy (OAC + clopidogrel) after acute phase (up to 1 week) in patients with atrial fibrillation requiring anticoagulation, as triple therapy significantly increases bleeding risk 4

The European Society of Cardiology recommends that for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) and a GRACE score >140, coronary angiography should be performed within 24 hours of hospital admission, while for patients with GRACE score ≤140, angiography can be safely delayed beyond 24 hours or managed with a selective invasive approach 12, 13

The European Society of Cardiology suggests that patients with hemodynamic instability, cardiogenic shock, recurrent or ongoing chest pain, life-threatening arrhythmias, or mechanical complications of myocardial infarction (MI) should proceed immediately to the catheterization laboratory, regardless of GRACE score 12
The European Society of Cardiology recommends that patients with a GRACE score >140 should undergo early invasive strategy, as this is the primary determinant for early invasive strategy timing in stabilized patients 12, 13

The TIMACS trial demonstrated that early intervention (median 14 hours) reduced the primary ischemic endpoint from 21.0% to 13.9% (HR 0.65, 95% CI 0.48-0.89, P=0.006) in patients with GRACE >140 14
The VERDICT trial confirmed this interaction, showing benefit with early invasive strategy only in patients with GRACE >140 (HR 0.81, 95% CI 0.67-1.00 vs HR 1.21, 95% CI 0.92-1.60 for GRACE ≤140; P for interaction=0.02) 13

The European Society of Cardiology recommends using the GRACE risk score for in-hospital death when applying the >140 threshold, as this is what the TIMACS and VERDICT trials validated 13

The European Society of Cardiology defines immediate angiography as <2 hours from hospital admission, early angiography as <24 hours, and delayed angiography as >24 hours 12, 15

Early invasive strategy in GRACE >140 patients significantly reduces refractory ischemia (3.3% vs 1.0%, P<0.001) and recurrent MI 16

The European Society of Cardiology recommends applying the same GRACE-based timing strategy in elderly patients (≥75 years) after careful evaluation of comorbidities, frailty, and life expectancy 12
The European Society of Cardiology suggests using identical GRACE thresholds and timing as non-diabetic patients in diabetic patients, as diabetes is already incorporated into the GRACE score calculation 12